Genelux Corp (GNLX) Financiero

Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.